CBER official overruled review team's rejection of new Replimune melanoma drug
RegulatoryapprovedTudriqevPositive
AI Analysis
Summary
The FDA's biologics center director Asha Das overruled the review team to grant accelerated approval to Replimune's melanoma drug Tudriqev in early August. The decision represents a significant regulatory milestone despite initial rejection by the agency's review team.
Outcome Details
Accelerated approval granted by CBER official Asha Das, overruling the review team's rejection
Importance:8/10
Sentiment:
0.80
FDA approvalaccelerated approvalmelanomaregulatory overrideoncology
Related Companies
Read the original article
Published by Endpoints News on September 2, 2026 4:02 PM